Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.

Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, Ha D, Shigeta N, Kitawaki T, Maeda Y, Saito T, Shinohara Y, Kameoka Y, Iwaisako K, Monma F, Ohishi K, Karbach J, Jäger E, Sawada K, Katayama N, Takahashi N, Sakaguchi S.

J Exp Med. 2019 Nov 8. pii: jem.20191009. doi: 10.1084/jem.20191009. [Epub ahead of print]

PMID:
31704808
2.

Vasculitis and crescentic glomerulonephritis in a newly established congenic mouse strain derived from ANCA-associated vasculitis-prone SCG/Kj mice.

Hamano Y, Ito F, Suzuki O, Koura M, Matsuoka S, Kobayashi T, Sugitani Y, Wali N, Koyanagi A, Hino O, Suzuki S, Sugamata R, Yoshizawa H, Yumura W, Maruyama N, Kameoka Y, Noda Y, Hasegawa Y, Arai T, Suzuki K.

Autoimmunity. 2019 Aug - Sep;52(5-6):208-219. doi: 10.1080/08916934.2019.1658191. Epub 2019 Sep 2.

PMID:
31476889
3.

Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.

Ikeda S, Kobayashi T, Saito M, Komatsuda A, Ubukawa K, Kameoka Y, Takahashi N.

Intern Med. 2019 Aug 6. doi: 10.2169/internalmedicine.2882-19. [Epub ahead of print]

4.

Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew).

Ubukawa K, Kameoka Y, Guo YM, Nara M, Watanabe A, Fujishima M, Fujishima N, Yoshioka T, Takahashi N.

Intern Med. 2019 Nov 1;58(21):3153-3156. doi: 10.2169/internalmedicine.2967-19. Epub 2019 Jul 10.

5.

Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum].

Kameoka Y, F K, M K.

Drug Des Devel Ther. 2019 May 22;13:1689. doi: 10.2147/DDDT.S212028. eCollection 2019. No abstract available.

6.

Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.

Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N.

Ann Hematol. 2019 Jul;98(7):1647-1655. doi: 10.1007/s00277-019-03689-9. Epub 2019 Apr 19.

PMID:
31001658
7.

Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis.

Kameoka Y, Kishi F, Koura M, Yamakawa Y, Nagasawa R, Ito F, Matsuda J, Suzuki O, Nakayama T, Suzuki K.

Drug Des Devel Ther. 2019 Feb 5;13:555-568. doi: 10.2147/DDDT.S188651. eCollection 2019. Erratum in: Drug Des Devel Ther. 2019 May 22;13:1689.

8.

Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation.

Kobayashi T, Guo YM, Yamashita T, Nara M, Yoshioka T, Kameoka Y, Fukuda T, Takahashi N.

Int J Hematol. 2019 Mar;109(3):356-360. doi: 10.1007/s12185-018-02584-9. Epub 2019 Jan 3.

PMID:
30604316
9.

Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.

Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N.

Int J Hematol. 2018 Nov;108(5):510-515. doi: 10.1007/s12185-018-2508-1. Epub 2018 Jul 24.

PMID:
30043334
10.

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.

Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H; STAT study group.

Haematologica. 2018 Nov;103(11):1835-1842. doi: 10.3324/haematol.2018.194894. Epub 2018 Jul 5.

11.

Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.

Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z.

PMID:
29736778
12.

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N.

Exp Hematol Oncol. 2018 Apr 13;7:9. doi: 10.1186/s40164-018-0101-1. eCollection 2018.

13.

The Rare Disease Bank of Japan: establishment, current status and future challenges.

Tada M, Hirata M, Sasaki M, Sakate R, Kohara A, Takahashi I, Kameoka Y, Masui T, Matsuyama A.

Hum Cell. 2018 Jul;31(3):183-188. doi: 10.1007/s13577-018-0204-3. Epub 2018 Apr 2.

PMID:
29611131
14.

Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.

Kobayashi T, Miura M, Niioka T, Abumiya M, Ito F, Kobayashi I, Ikeda S, Yoshioka T, Kameoka Y, Takahashi N.

Ther Drug Monit. 2018 Jun;40(3):301-309. doi: 10.1097/FTD.0000000000000499.

PMID:
29494421
15.

A genome-wide screen for FTY720-sensitive mutants reveals genes required for ROS homeostasis.

Hagihara K, Kinoshita K, Ishida K, Hojo S, Kameoka Y, Satoh R, Takasaki T, Sugiura R.

Microb Cell. 2017 Nov 27;4(12):390-401. doi: 10.15698/mic2017.12.601.

16.

Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.

Fujishima M, Fujishima N, Kitadate A, Guo Y, Watanabe A, Ubukawa K, Nara M, Yoshioka T, Kameoka Y, Takahashi N.

Rinsho Ketsueki. 2017;58(7):743-748. doi: 10.11406/rinketsu.58.743. Japanese.

PMID:
28781268
17.

The human vascular endothelial cell line HUV-EC-C harbors the integrated HHV-6B genome which remains stable in long term culture.

Shioda S, Kasai F, Ozawa M, Hirayama N, Satoh M, Kameoka Y, Watanabe K, Shimizu N, Tang H, Mori Y, Kohara A.

Cytotechnology. 2018 Feb;70(1):141-152. doi: 10.1007/s10616-017-0119-y. Epub 2017 Jul 28.

18.

Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.

Nara M, Komatsuda A, Itoh F, Kaga H, Saitoh M, Togashi M, Kameoka Y, Wakui H, Takahashi N.

Intern Med. 2017;56(10):1247-1252. doi: 10.2169/internalmedicine.56.7991. Epub 2017 May 15.

19.

Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum.

Int J Hematol. 2017 May;105(5):606-613. doi: 10.1007/s12185-017-2190-8. Epub 2017 Feb 7.

PMID:
28176226
20.

[TAFRO Syndrome with Bilateral Adrenal Hemorrhage].

Ito F, Kameoka Y, Nara M, Ubukawa K, Fujishima M, Yoshioka T, Fujishima N, Takahashi N.

Nihon Naika Gakkai Zasshi. 2017 Feb;106(2):288-94. Japanese. No abstract available.

PMID:
30182658
21.

Retinoylation (covalent modification by retinoic acid) of Rho-GDIβ in the human myeloid leukemia cell line HL60 and its functional significance.

Takahashi N, Ohba T, Imai M, Hasegawa S, Takahashi K, Yamasaki M, Kameoka Y.

Biochim Biophys Acta. 2016 Dec;1861(12 Pt A):2011-2019. doi: 10.1016/j.bbalip.2016.10.001. Epub 2016 Oct 6.

PMID:
27720952
22.

Transcatheter Arterial Embolization with a Mixture of Absolute Ethanol and Iodized Oil for Poorly Visualized Endophytic Renal Masses Prior to CT-Guided Percutaneous Cryoablation.

Michimoto K, Shimizu K, Kameoka Y, Sadaoka S, Miki J, Kishimoto K.

Cardiovasc Intervent Radiol. 2016 Nov;39(11):1589-1594. doi: 10.1007/s00270-016-1414-2. Epub 2016 Jul 5.

PMID:
27380871
23.

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.

Yamashita T, Fujishima N, Miura M, Niioka T, Abumiya M, Shinohara Y, Ubukawa K, Nara M, Fujishima M, Kameoka Y, Tagawa H, Hirokawa M, Takahashi N.

Cancer Chemother Pharmacol. 2016 Jul;78(1):111-8. doi: 10.1007/s00280-016-3060-4. Epub 2016 May 23.

24.

[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].

Hishiki H, Ishiwada N, Naito S, Nagasawa K, Someya T, Inoue N, Haraki M, Kurosaki T, Kameoka Y, Suzuki K.

Jpn J Antibiot. 2015 Dec;68(6):337-43. Japanese.

PMID:
27004397
25.

Development and evaluation of immunochromatography to detect Gram-negative bacteria producing ArmA 16S rRNA methylase responsible for aminoglycoside resistance.

Oshiro S, Tada T, Kameoka Y, Suzuki K, Ohmagari N, Miyoshi-Akiyama T, Kirikae T.

J Microbiol Methods. 2015 Nov;118:159-63. doi: 10.1016/j.mimet.2015.09.005. Epub 2015 Sep 14.

PMID:
26381663
26.

Reactivation of CDX2 in Gastric Cancer as Mark for Gene Silencing Memory.

Kameoka Y, Kitazawa R, Ariasu K, Tachibana R, Mizuno Y, Haraguchi R, Kitazawa S.

Acta Histochem Cytochem. 2015 Aug 27;48(4):115-24. doi: 10.1267/ahc.15014. Epub 2015 Aug 20.

27.

Transcatheter embolization for hemoptysis associated with anomalous systemic artery in a patient with scimitar syndrome.

Yamakawa H, Shimizu K, Michimoto K, Kameoka Y, Kang R, Yoshida J, Yamada M, Yoshida M, Ishikawa T, Takagi M, Kuwano K.

Springerplus. 2015 Aug 14;4:422. doi: 10.1186/s40064-015-1219-9. eCollection 2015.

28.

Correction: Transcriptional Dynamics of Immortalized Human Mesenchymal Stem Cells during Transformation.

Takeuchi M, Higashino A, Takeuchi K, Hori Y, Koshiba-Takeuchi K, Makino H, Monobe Y, Kishida M, Adachi J, Takeuchi J, Tomonaga T, Umezawa A, Kameoka Y, Akagi K.

PLoS One. 2015 Jun 22;10(6):e0131383. doi: 10.1371/journal.pone.0131383. eCollection 2015. No abstract available.

29.

Transcriptional Dynamics of Immortalized Human Mesenchymal Stem Cells during Transformation.

Takeuchi M, Higashino A, Takeuchi K, Hori Y, Koshiba-Takeuchi K, Makino H, Monobe Y, Kishida M, Adachi J, Takeuchi J, Tomonaga T, Umezawa A, Kameoka Y, Akagi K.

PLoS One. 2015 May 15;10(5):e0126562. doi: 10.1371/journal.pone.0126562. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0131383.

30.

Digestive Tract Complications of Renal Cryoablation.

Shimizu K, Mogami T, Michimoto K, Kameoka Y, Tokashiki T, Kurata N, Miki J, Kishimoto K.

Cardiovasc Intervent Radiol. 2016 Jan;39(1):122-6. doi: 10.1007/s00270-015-1110-7. Epub 2015 May 6.

PMID:
25944148
31.

A successful case of liver biopsy via the right femoral vein using the Quick-Core biopsy needle.

Michimoto K, Shimizu K, Kameoka Y, Kurata N, Tokashiki T, Sadaoka S, Fukuda K.

Jpn J Radiol. 2015 May;33(5):295-7. doi: 10.1007/s11604-015-0414-5. Epub 2015 Mar 17.

PMID:
25776132
32.

Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma.

Kameoka Y, Takahashi N, Itou S, Kume M, Noji H, Kato Y, Ichikawa Y, Sasaki O, Motegi M, Ishiguro A, Tagawa H, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Sawada K.

Int J Hematol. 2015 Jun;101(6):536-42. doi: 10.1007/s12185-015-1763-7. Epub 2015 Mar 5.

PMID:
25739382
33.

Treatment of multiple myeloma in Akita: features and outcomes in the era of novel agents.

Shida S, Takahashi N, Niioka T, Kitabayashi A, Kawabata Y, Kume M, Saitoh H, Hatano Y, Ichikawa Y, Kuroki J, Motegi M, Kobayashi T, Kameoka Y, Tagawa H, Fujishima N, Yoshioka T, Hirokawa M, Miura M, Sawada K.

J Clin Exp Hematop. 2014;54(1):89-93. No abstract available.

34.

Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.

Abumiya M, Takahashi N, Niioka T, Kameoka Y, Fujishima N, Tagawa H, Sawada K, Miura M.

Drug Metab Pharmacokinet. 2014;29(6):449-54. doi: 10.2133/dmpk.DMPK-14-RG-031. Epub 2014 Jun 3.

35.

A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.

Shida S, Takahashi N, Miura M, Niioka T, Matsumoto M, Hagihara M, Kobayashi T, Abumiya M, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K.

Ther Drug Monit. 2014 Aug;36(4):505-9. doi: 10.1097/FTD.0000000000000034.

PMID:
24562046
36.

Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.

Nagao T, Takahashi N, Kameoka Y, Noguchi S, Shinohara Y, Ohyagi H, Kume M, Sawada K.

Intern Med. 2013;52(22):2567-71. Review.

37.

Finding the factors of reduced genetic diversity on X chromosomes of Macaca fascicularis: male-driven evolution, demography, and natural selection.

Osada N, Nakagome S, Mano S, Kameoka Y, Takahashi I, Terao K.

Genetics. 2013 Nov;195(3):1027-35. doi: 10.1534/genetics.113.156703. Epub 2013 Sep 11.

38.
39.

Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants.

Nara M, Takahashi N, Miura M, Niioka T, Kagaya H, Fujishima N, Saitoh H, Kameoka Y, Tagawa H, Hirokawa M, Sawada K.

Eur J Clin Pharmacol. 2013 Jun;69(6):1321-9. doi: 10.1007/s00228-013-1471-2. Epub 2013 Jan 26.

PMID:
23354810
40.

[Adult T-cell leukemia-lymphoma developed from an HTLV-1 carrier during treatment of B-cell lymphoma-associated hemophagocytic syndrome].

Nagao T, Takahashi N, Saitoh H, Noguchi S, Guo YM, Ito M, Watanabe A, Fujishima N, Kameoka Y, Tagawa H, Hirokawa M, Sawada K.

Rinsho Ketsueki. 2012 Dec;53(12):2008-12. Japanese.

PMID:
23318967
41.

CDR3-independent expansion of Vδ1 T lymphocytes in acquired chronic pure red cell aplasia.

Michishita Y, Hirokawa M, Fujishima N, Abe Y, Fujishima M, Guo YM, Ubukawa K, Liu J, Yoshioka T, Kameoka Y, Saitoh H, Tagawa H, Takahashi N, Sawada K.

Immunol Lett. 2013 Feb;150(1-2):23-9. doi: 10.1016/j.imlet.2012.12.006. Epub 2012 Dec 27.

PMID:
23274961
42.

Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.

Noguchi S, Takahashi N, Ito M, Teshima K, Yamashita T, Michishita Y, Ohyagi H, Shida S, Nagao T, Fujishima M, Ikeda S, Ito I, Fujishima N, Kameoka Y, Saitoh H, Tagawa H, Hirokawa M, Sawada K.

Int J Clin Oncol. 2013 Dec;18(6):983-7. doi: 10.1007/s10147-012-0485-6. Epub 2012 Oct 18.

PMID:
23076821
43.

Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.

Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, Murai K, Noji H, Hirokawa M, Tajima K, Shichishima T, Ishida Y, Harigae H, Sawada K.

Int J Hematol. 2012 Nov;96(5):624-30. doi: 10.1007/s12185-012-1186-7. Epub 2012 Oct 1.

PMID:
23054649
44.

Whole-genome sequencing and analysis of the Malaysian cynomolgus macaque (Macaca fascicularis) genome.

Higashino A, Sakate R, Kameoka Y, Takahashi I, Hirata M, Tanuma R, Masui T, Yasutomi Y, Osada N.

Genome Biol. 2012 Jul 2;13(7):R58. doi: 10.1186/gb-2012-13-7-r58.

45.

T-cell prolymphocytic leukemia in Japan: is it a variant?

Kameoka J, Takahashi N, Noji H, Murai K, Tajima K, Kameoka Y, Sato S, Shichishima T, Ishida Y, Harigae H, Sawada K.

Int J Hematol. 2012 Jun;95(6):660-7. doi: 10.1007/s12185-012-1077-y. Epub 2012 Apr 24.

PMID:
22527853
46.

Drug interaction between lenalidomide and itraconazole.

Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K.

Am J Hematol. 2012 Mar;87(3):338-9. doi: 10.1002/ajh.22260. Epub 2011 Dec 27. No abstract available.

47.

False-positive human immunodeficiency virus antibody test and autoimmune hemolytic anemia in a patient with angioimmunoblastic T-cell lymphoma.

Shida S, Takahashi N, Fujishima N, Kameoka Y, Nara M, Fujishima M, Saitoh H, Tagawa H, Hirokawa M, Ichinohasama R, Sawada K.

Intern Med. 2011;50(20):2383-7. Epub 2011 Oct 15.

48.

Successful treatment of necrotizing fasciitis in an upper extremity caused by Clostridium perfringens after bone marrow transplantation.

Ito M, Takahashi N, Saitoh H, Shida S, Nagao T, Kume M, Kameoka Y, Tagawa H, Fujishima N, Hirokawa M, Tazawa H, Minato T, Yamada S, Sawada K.

Intern Med. 2011;50(19):2213-7. Epub 2011 Oct 1.

49.

Age-associated alteration of γδ T-cell repertoire and different profiles of activation-induced death of Vδ1 and Vδ2 T cells.

Michishita Y, Hirokawa M, Guo YM, Abe Y, Liu J, Ubukawa K, Fujishima N, Fujishima M, Yoshioka T, Kameoka Y, Saito H, Tagawa H, Takahashi N, Sawada K.

Int J Hematol. 2011 Sep;94(3):230-240. doi: 10.1007/s12185-011-0907-7. Epub 2011 Aug 20.

PMID:
21858446
50.

Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient.

Miura M, Takahashi N, Kanno S, Kato S, Nara M, Itoh M, Saitoh H, Yoshioka T, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K.

Clin Chim Acta. 2011 Oct 9;412(21-22):2002-6. doi: 10.1016/j.cca.2011.06.035. Epub 2011 Jul 21.

PMID:
21771587

Supplemental Content

Loading ...
Support Center